Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease

Adult Polycystic Kidney Disease Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02062671
• Other study ID #: RePKID
• Secondary ID: S-20130085
• Status: Recruiting
• Phase: N/A
• First received: February 12, 2014
• Last updated: February 13, 2014
• Start date: February 2014
• Est. completion date: February 2015

Study information

• Verified date: February 2014
• Source: Odense University Hospital
• Contact: Hans Dieperink, MD
• Phone: +4520598851
• Email: hans.dieperink[@]rsyd.dk
• Is FDA regulated: No
• Health authority: Denmark: The Ethics Comitee for Southern Denmark
• Study type: Interventional

Clinical Trial Summary

In patients with polycystic kidney disease, pain may be resistant to drug therapy and may reduce quality of life. This study investigate the effect of renal denervation on this pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pain limiting daily activities in spite of pain killers, ADPKD

Exclusion Criteria:

• Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adult Polycystic Kidney Disease
• Kidney Diseases
• Polycystic Kidney Diseases
• Polycystic Kidney, Autosomal Dominant

Intervention

Procedure:
• renal denervation

Locations

Country	Name	City	State
Denmark	Department of Nephrology	Odense

Sponsors (1)

Lead Sponsor	Collaborator
Odense University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	kidney function	creatinine clearance	6 months	Yes
Primary	Pain	Pain from VAS	6 months	No
Secondary	Quality of Life (QoL)	SF-12v2	6 months	No